About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. (CRL) has been publicly traded since 2000, making it a 26-year-old public company. It operates in the Diagnostics & Research industry within the Healthcare sector. The company is headquartered in Wilmington, United States and employs approximately 18,300 people. With a market capitalization of $7.7 billion, CRL is a mid-sized company with growth potential.
Key Statistics
- Current Price
- $155.46
- Market Cap
- $7.65B
- 52-Week High
- $228.88
- 52-Week Low
- $91.86
- Sector
- Healthcare
- Industry
- Diagnostics & Research
$1,000 Invested
Monthly Returns Heatmap
Annual Returns
| Year | Return | Start | End |
|---|---|---|---|
| 2026 | -22.07% | $199.48 | $155.46 |
| 2025 | +8.06% | $184.60 | $199.48 |
| 2024 | -21.91% | $236.40 | $184.60 |
| 2023 | +8.49% | $217.90 | $236.40 |
| 2022 | -42.17% | $376.78 | $217.90 |
| 2021 | +50.80% | $249.86 | $376.78 |
| 2020 | +63.56% | $152.76 | $249.86 |
| 2019 | +34.97% | $113.18 | $152.76 |
| 2018 | +3.41% | $109.45 | $113.18 |
| 2017 | +43.65% | $76.19 | $109.45 |
| 2016 | -5.22% | $80.39 | $76.19 |
| 2015 | +26.32% | $63.64 | $80.39 |
| 2014 | +19.98% | $53.04 | $63.64 |
| 2013 | +41.55% | $37.47 | $53.04 |
| 2012 | +37.10% | $27.33 | $37.47 |
| 2011 | -23.10% | $35.54 | $27.33 |
| 2010 | +5.49% | $33.69 | $35.54 |
| 2009 | +28.59% | $26.20 | $33.69 |
| 2008 | -60.18% | $65.80 | $26.20 |
| 2007 | +52.14% | $43.25 | $65.80 |
| 2006 | +2.08% | $42.37 | $43.25 |
| 2005 | -7.91% | $46.01 | $42.37 |
| 2004 | +34.02% | $34.33 | $46.01 |
| 2003 | -10.78% | $38.48 | $34.33 |
| 2002 | +14.93% | $33.48 | $38.48 |
| 2001 | +22.30% | $27.38 | $33.48 |
Valuation
The forward P/E ratio is 12.7. The price-to-book ratio stands at 2.4. The price-to-sales ratio is 1.9.
Dividends
Charles River Laboratories International, Inc. does not currently pay a dividend, choosing to reinvest earnings back into the business for growth.
Risk & Volatility
CRL has a beta of 1.65, indicating it is significantly more volatile than the overall market. The stock's 52-week range is $91.86 to $228.88, and it currently trades in the lower half of its 52-week range.
Analyst Ratings
Based on 15 analyst opinions, CRL has a consensus "buy" rating. The average price target of $197.47 suggests 27.0% upside from current levels.
Frequently Asked Questions
What does Charles River Laboratories International, Inc. do? ▼
Charles River Laboratories International, Inc. is a Diagnostics & Research company operating in the Healthcare sector. The company is headquartered in Wilmington, United States.
What sector is CRL in? ▼
CRL operates in the Healthcare sector, specifically in the Diagnostics & Research industry.
When did CRL go public? ▼
Charles River Laboratories International, Inc. went public in 2000, making it a 26-year-old public company as of 2026.
How much would $1,000 invested in CRL 5 years ago be worth today? ▼
A $1,000 investment in CRL five years ago would be worth approximately $558 today, representing a -44.2% return.
Does CRL pay dividends? ▼
No, Charles River Laboratories International, Inc. does not currently pay a dividend. The company reinvests its earnings into growth.
What is CRL's market cap? ▼
Charles River Laboratories International, Inc. has a market capitalization of $7.7 billion, classifying it as a mid-cap company.
Is CRL a buy, hold, or sell? ▼
Based on 15 opinions, CRL has a consensus "buy" rating. The average price target is $197.47.
Last updated: 3/14/2026